All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Early Use of ctDNA May Accelerate Time to Treatment and Improve Survival in NSCLC

November 11th 2023

While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.

IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

November 11th 2023

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Research Aims to Make Inroads With CAR T-Cell Therapy in Advanced RCC

November 11th 2023

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Deeper Understanding of Clonal Hematopoiesis Could Improve Cardiovascular Outcomes for Patients With Kidney Cancer

November 11th 2023

Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events.

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC

November 11th 2023

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Treatment Decisions in RCC Could Be Aided by ctDNA

November 11th 2023

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

Management of irAEs in Cancer Care Requires Novel Strategies Beyond Steroids

November 11th 2023

Although the emergence of immunotherapy have created additional treatment options for patients with various types of cancer, these agents are associated with significant toxicities and immune-related adverse effects.

Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV

November 11th 2023

The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.

LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC

November 11th 2023

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Zanzalintinib Continues to Elicit Efficacy With Tolerability in Advanced ccRCC

November 10th 2023

Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.

Considering the Data Behind Belzutifan's Approval in VHL Disease–Associated Cancers

November 10th 2023

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management

November 10th 2023

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

Reflecting on Advances Made in High-Risk, Low-Grade Prostate Cancer Management

November 10th 2023

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer

November 10th 2023

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

Treatments for Translocation RCC Require Novel Therapeutic Targets

November 10th 2023

Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.

Frontline Pembrolizumab Plus Chemo Approaches EU Approval for Biliary Tract Cancer

November 10th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) combined with gemcitabine and cisplatin in the frontline treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer

Fox Chase Researcher Henkel Valentine Recognized as an IMPACT Fellow by the National Postdoctoral Association

November 10th 2023

Henkel Valentine, PhD, a postdoctoral fellow in the lab of Philip Abbosh, MD, PhD, in the Nuclear Dynamics and Cancer Research Program at Fox Chase Cancer Center, was one of six postdoctoral researchers nationwide recently recognized as an IMPACT Fellow by the National Postdoctoral Association.

Pursuit of Effective Agents Continues in Multiple Types of Sarcomas

November 10th 2023

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

Fox Chase Cancer Center’s Dr. Alexander Kutikov to Receive Andrew C. Novick Award at 2023 International Kidney Cancer Symposium

November 10th 2023

Alexander Kutikov, MD, FACS, chair of the Department of Urology and the Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center, will receive the Andrew C. Novick Award from the Kidney Cancer Association.

Unique Molecular Profiles of Biliary Tract Cancers Drive Continued Development of Targeted Therapies

November 9th 2023

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.